Assessment of post-op IOL optic changes with AS-OCT

Article

Advantages found for location and density of intraoptic changes

Methods and results

IOLs explanted because of different complications and sent to the Intermountain Ocular Research Center at the John A. Moran Eye Center, University of Utah were used. These included the following:

Gross and light microscopy of the single-piece hydrophobic acrylic lenses in the dry state showed no optic opacification and absence of glistenings within their optics. The corresponding AS-OCT scans only showed the overall outline of the surfaces of the lenses. Removal of the lenses from warm solution and analysis at room temperature caused formation of intraoptic glistenings, which was confirmed under light microscopy. Corresponding ASOCT scans showed that the glistenings were overall homogeneously distributed within the entire optic, but sometimes absent in a small subsurface area.

Gross examination of the cadaver eyes from the MiyakeApple view revealed the presence of single-piece hydrophilic acrylic lenses implanted in the capsular bag, exhibiting overall a clear optic. ASOCT scans of the lenses, obtained before and after explantation from the cadaver eyes showed their overall outline, confirming the absence of any intraoptic changes. The ASOCT outline of these lenses appeared thinner and less bright than in the cases with calcification.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.